Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia

被引：0
|
作者：
Takahiro Kambara
Rei Shibata
Yuusuke Sakamoto
Teruhiro Sakaguchi
Hiroyuki Osanai
Yoshihito Nakashima
Hiroshi Asano
Toyoaki Murohara
Masayoshi Ajioka
机构：
[1] Tosei General Hospital,Department of Cardiovascular Medicine
[2] Nagoya University Graduate School of Medicine,Department of Advanced Cardiovascular Therapeutics
[3] Nagoya University Graduate School of Medicine,Department of Cardiology
来源：
BMC Research Notes | / 17卷
关键词：
Heart failure; HIF-PH inhibitor; NT-proBNP; Renal anemia; Ferritin; TSAT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Preferred Conformation-Guided Discovery of Potent and Orally Active HIF Prolyl Hydroxylase 2 Inhibitors for the Treatment of Anemia
    Wu, Yue
    Zhang, Linjian
    Sun, Zhuoli
    Qiu, Xusheng
    Chen, Yafen
    Su, Kaijun
    Yang, Le
    Du, Zhongqiu
    Dong, Ying
    Yang, Fulai
    Li, Xiang
    Zhang, Xiaojin
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (13) : 8545 - 8563
  • [32] Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia
    Packer, Milton
    AMERICAN JOURNAL OF NEPHROLOGY, 2024, 55 (02) : 255 - 259
  • [33] The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia
    Imai, Enyu
    Imai, Atsuhiro
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (11) : 1090 - 1096
  • [34] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Anemia in CKD
    Parfrey, Patrick
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (25): : 2390 - 2391
  • [35] Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases
    Joharapurkar, Amit A.
    Pandya, Vrajesh B.
    Patel, Vishal J.
    Desai, Ranjit C.
    Jain, Mukul R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (16) : 6964 - 6982
  • [36] Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    McMahon, Gearoid M.
    Singh, Ajay K.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2019, 28 (06): : 600 - 606
  • [37] HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
    Poloznikov, Andrey A.
    Nersisyan, Stepan A.
    Hushpulian, Dmitry M.
    Kazakov, Eliot H.
    Tonevitsky, Alexander G.
    Kazakov, Sergey, V
    Vechorko, Valery, I
    Nikulin, Sergey, V
    Makarova, Julia A.
    Gazaryan, Irina G.
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [38] Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and Enarodustat
    Corner, Thomas P.
    Salah, Eidarus
    Tumber, Anthony
    Kaur, Samanpreet
    Nakashima, Yu
    Allen, Mark D.
    Schnaubelt, Lara I.
    Fiorini, Giorgia
    Brewitz, Lennart
    Schofield, Christopher J.
    CHEMMEDCHEM, 2024, 19 (24)
  • [39] Identification of novel potential HIF-prolyl hydroxylase inhibitors by in silico screening
    Teli, Mahesh Kumar
    Rajanikant, G. K.
    MOLECULAR DIVERSITY, 2012, 16 (01) : 193 - 202
  • [40] ROXADUSTAT Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of Anemia
    Virgili-Lopez, G.
    DRUGS OF THE FUTURE, 2014, 39 (11) : 783 - 791
12345